<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14771">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01668108</url>
  </required_header>
  <id_info>
    <org_study_id>ONKOPAC 01</org_study_id>
    <nct_id>NCT01668108</nct_id>
  </id_info>
  <brief_title>A Non Interventional Study With Paclitaxel Onkovis (Paclitaxel) Utilized for the Treatment of Cancer</brief_title>
  <official_title>Open, Multicenter Observational Study of Paclitaxel Utilized in Mono- or Combination Therapy for the Treatment of Breast Cancer, Non-small Cell Lung Cancer and Ovarial Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onkovis GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AKP Freiburg GmbH (Clinical Research Organization)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Onkovis GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this observational study with Paclitaxel is to determine the number of
      treatment cycles and the quantity of Paclitaxel onkovis needed therefore under the special
      circumstance of ambulant chemotherapy.

      onkovis aims an economical utilization of the chemotherapeutics.The provision with adapted
      packaging sizes as to decrease the excess quantity to be discarded follows also this
      objective.

      Secondary objectives are the survey of the side effects of Paclitaxel onkovis in comparison
      to Docetaxel. To this purpose, data regarding co medications and adverse events are also
      collected.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>the quantity of Paclitaxel onkovis needed pro treatment cycle</measure>
    <time_frame>the time the participants will be followed depends on the number of treatment cycles; that means the time frame may extend up to 24 weeks (8 cycles).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine the quantity of Paclitaxel onkovis needed pro treatment cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events during and after treatment in comparison to Docetaxel onkovis</measure>
    <time_frame>up to 24 weeks (8 cycles)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number and kind of adverse events during and after the intra-venous application of Paclitaxel will be assessed, documented and compared to those of Docetaxel.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>carcinoma, Paclitaxel onkovis (Paclitaxel)</arm_group_label>
    <description>treatment in mono- or combination therapy with Paclitaxel of breast-, non-small cell lung- and ovarial cancer.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated in practices, clinics, hospitals
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for Paclitaxel according to the SmPC and treating physician

        Exclusion Criteria:

          -  according to the Paclitaxel SmPC
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>K.-U. Seiler, PD Dr. med.</last_name>
    <phone>+49(0)761479400</phone>
    <email>info@akp-freiburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Brandenburg</city>
        <zip>14770</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Chemnitz</city>
        <zip>09117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>MÃ¼hlhausen</city>
        <zip>99974</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Plauen</city>
        <zip>08525</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>August 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carcinoma</keyword>
  <keyword>breast cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>ovarial cancer</keyword>
  <keyword>ambulant chemotherapy</keyword>
  <keyword>treatment cycles</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Paclitaxel onkovis</keyword>
  <keyword>Quantity of Paclitaxel</keyword>
  <keyword>Packaging Sizes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
